HIGHLIGHTS
SUMMARY
Background: in_vivo PSMA‑PET imaging in prostate cancer PCa is the most frequent malignancy in men, and it is still considered one of the three "big killers" together with lung cancer and breast cancer. One of the main limitations for PSMA-PET in staging PCa is represented by the low sensitivity in identifying metastatic lymph nodes. PSMA-RGS can be performed with gamma-ray probes, detecting single photon emitting isotopes (e_g Technetium-99 m or Indium-111 labelled with PSMA inhibitors) or with beta-ray probes, detecting the radiation emitted by routinely used PET . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.